Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Spero Therapeutics Inc

SPRO ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: HOLD

Last Close

$1.23

▼ -0.81%

Market Cap $71.63M · Vol 158.70K

Key Metrics

P/E Ratio

7.13

FWD: 4.11

Market Cap

$71.63M

Micro Cap

Div Yield

N/A

EPS Growth

-293.33%

YoY

RSI (14)

57.35

Momentum

Beta

1.48

vs Market

52W High

$3.08

60.06% below

52W Low

$1.08

13.89% above

Volume

158.70K

Avg 348.48K

P/B

2.23

Price-to-book

ROE

N/A

Return on equity

Free Float

77.34%

Public shares

Shariah Compliance8 STANDARDS

✗ Spero Therapeutics Inc (SPRO) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does SPRO pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.38%

-27.65%

-55.43%

-48.54%

YTD

-47.21%

-37.88%

-8.55%

-90.90%

Financials & Valuation

TTM · Annual

Total Revenue	$66.80M
Net Income	$8.57M
Revenue Growth (YoY)	-95.61%
Gross Margin	100.00%
Operating Margin	10.72%
Net Profit Margin	12.83%
ROE	N/A
ROA · ROIC	9.84% · 16.31%

P/E Ratio	7.13
Forward P/E (FY1)	4.11
PEG Ratio	0.14
P/S	2.06
P/B	2.23
P/FCF	N/A
EPS Growth	-293.33%
Outstanding Shares	58.23M

Technical Indicators

50-Day SMA	$1.86
200-Day SMA	$2.31
RSI (14)	57.35
Beta	1.48
52-Week High	$3.08
52-Week Low	$1.08

Volume Today	158.70K
Avg Daily Volume (30D)	348.48K
Relative Volume	0.46x
Volatility (10D)	46.66
Volatility (30D)	89.12
Free Float	77.34%

Analyst Consensus

HOLD

Current Price $1.23

Mean Target $4.00

52W Low$1.08 52W High$3.08

Current

Target

$1.08 $3.08

Current Analyst target

+225.20% upside potential · 1 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00HXSJ1S1

ISINUS84833T1034

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 13, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.